Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Jun;69(6):512–515. doi: 10.1136/hrt.69.6.512

Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.

J G Cleland 1, D Shah 1, S Krikler 1, A Dritsas 1, P Nihoyannopoulos 1, G Frost 1, C M Oakley 1
PMCID: PMC1025162  PMID: 8393685

Abstract

OBJECTIVE--To determine the cardiac, renal, and neuroendocrine effects of lisinopril in men with untreated, symptom free left ventricular systolic dysfunction. DESIGN--A randomised, double blind cross over trial with six week treatment periods to compare lisinopril (10 mg/day) and matching placebo. SETTING--Hospital outpatient department. PATIENTS--Patients with pronounced systolic dysfunction on cross sectional echocardiography due to myocardial infarction at least six months previously, without angina and with no or minimal breathlessness. Eighteen men were identified of whom 15 completed the study. INTERVENTIONS--Lisinopril (10 mg) or placebo given once daily by mouth. MAIN OUTCOME MEASURES--Primary: oxygen consumption at peak exercise. Secondary: resting cardiac function as measured by radionuclide ventriculography and echocardiography, renal function estimated radioisotopically, and plasma indices of neuroendocrine activity. RESULTS--Compared with placebo, lisinopril increased (mean (SD)) peak oxygen consumption during exercise (19.8(3.1) ml/kg/min v 21.4(3.2) ml/kg/min; p < 0.003). Lisinopril did not improve indices of cardiac function at rest. It reduced plasma concentrations of angiotensin II (median values 7 pg/ml to 5 pg/ml; p < 0.02), aldosterone (median values 113 pg/ml to 66 pg/ml; p < 0.05) and atrial natriuretic peptide (median values 69 pg/ml to 40 pg/ml; p < 0.04), but noradrenaline and antidiuretic hormone concentrations did not change. Renal blood flow increased and glomerular filtration rate declined. CONCLUSIONS--Even before the onset of heart failure lisinopril improves the cardiopulmonary response to exercise in patients with systolic ventricular dysfunction.

Full text

PDF
512

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cleland J. G., Henderson E., McLenachan J., Findlay I. N., Dargie H. J. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol. 1991 Mar 1;17(3):733–739. doi: 10.1016/s0735-1097(10)80192-5. [DOI] [PubMed] [Google Scholar]
  4. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  5. Dickstein K., Barvik S., Aarsland T. Effects of long-term enalapril therapy on cardiopulmonary exercise performance after myocardial infarction. Circulation. 1991 Jun;83(6):1895–1904. doi: 10.1161/01.cir.83.6.1895. [DOI] [PubMed] [Google Scholar]
  6. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–1729. doi: 10.1161/01.cir.82.5.1724. [DOI] [PubMed] [Google Scholar]
  7. Giles T. D., Katz R., Sullivan J. M., Wolfson P., Haugland M., Kirlin P., Powers E., Rich S., Hackshaw B., Chiaramida A. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989 May;13(6):1240–1247. doi: 10.1016/0735-1097(89)90294-5. [DOI] [PubMed] [Google Scholar]
  8. Lipkin D. P., Canepa-Anson R., Stephens M. R., Poole-Wilson P. A. Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J. 1986 May;55(5):439–445. doi: 10.1136/hrt.55.5.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McAlpine H. M., Morton J. J., Leckie B., Rumley A., Gillen G., Dargie H. J. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988 Aug;60(2):117–124. doi: 10.1136/hrt.60.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morton J. J., Webb D. J. Measurement of plasma angiotensin II. Clin Sci (Lond) 1985 Apr;68(4):483–484. doi: 10.1042/cs0680483. [DOI] [PubMed] [Google Scholar]
  11. Peters A. M., Gunasekera R. D., Henderson B. L., Brown J., Lavender J. P., De Souza M., Ash J. M., Gilday D. L. Noninvasive measurement of blood flow and extraction fraction. Nucl Med Commun. 1987 Oct;8(10):823–837. doi: 10.1097/00006231-198710000-00009. [DOI] [PubMed] [Google Scholar]
  12. Richards A. M., Cleland J. G., Tonolo G., McIntyre G. D., Leckie B. J., Dargie H. J., Ball S. G., Robertson J. I. Plasma alpha natriuretic peptide in cardiac impairment. Br Med J (Clin Res Ed) 1986 Aug 16;293(6544):409–412. doi: 10.1136/bmj.293.6544.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  14. Urata H., Healy B., Stewart R. W., Bumpus F. M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990 Apr;66(4):883–890. doi: 10.1161/01.res.66.4.883. [DOI] [PubMed] [Google Scholar]
  15. Watkins L., Jr, Burton J. A., Haber E., Cant J. R., Smith F. W., Barger A. C. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest. 1976 Jun;57(6):1606–1617. doi: 10.1172/JCI108431. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES